Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Genitourinary 4Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × sulindac sulfone × Genitourinary × Clear all
NCT00283803 2018-08-07

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

University of Washington

Phase 2 Completed
32 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT00052845 2016-07-01

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Alliance for Clinical Trials in Oncology

Phase 2 Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00078910 2013-06-24

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
130 enrolled
Genitourinary

Prostatic Neoplasms

NCT00166426 2009-11-16

Exisulind Versus Placebo After Surgical Removal of the Prostate

Mayo Clinic

Phase 2 Completed
240 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡